• 中等疾病活动度的RA患者持续传统治疗的结果:来自ERAN的数据


    原文

    译文

    Rheumatology (Oxford). 2010 Dec 17. [Epub ahead of print]

    Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity--the early RA network (ERAN).

    Kiely P, Walsh D, Williams R, Young A; for the Early Rheumatoid Arthritis Network (ERAN).

     

    Abstract

    Objective. To report from early RA network (ERAN) on Years 2 and 3 28-joint DAS (DAS-28) and HAQ outcomes in newly diagnosed RA patients treated with DMARD therapies stratified to DAS-28 status after 1 year.

    Methods. ERAN is a prospective observational cohort of newly diagnosed RA patients, monitored and treated according to local practice. Standardized case report forms are completed at first presentation, 3-6 months, 1 year and annually thereafter.

    Results. A total of 418 newly diagnosed RA patients with 2 years and 302 with 3 years follow-up were identified in 22 ERAN centres from 2002 to 2008. Within their first year from registration, 67% of patients received monotherapy DMARDs, and 26% combination DMARDs including 2% were on anti-TNF therapies. Between Years 1 and 3, 60% received DMARD monotherapy, 34% combination DMARD therapy including 8% on anti-TNF therapies. Seventy-four per cent of patients with Year 1 DAS-28 <3.2 and 27% with DAS-28 3.2-5.1 achieved a DAS-28 <3.2 outcome at Year 2 [odds ratio (OR) 7.64; 95% CI 4.6, 12.6], and 71 and 35%, respectively, at Year 3 (OR 4.49; 95% CI 2.5, 7.9). Seventy-nine per cent of patients with a Year 1 DAS-28 <3.2 and 52% with DAS-28 3.2-5.1 achieved an HAQ <1.25 at Year 2 (OR 3.47; 95% CI 2.1, 5.6), and 81 and 47%, respectively, at Year 3 (OR 4.92; 95% CI 2.6, 9.0).

    Conclusions. In RA patients with a DAS-28 3.2-5.1 at 1 year, the likelihood of achieving a target low DAS-28 <3.2, or a low HAQ, at Years 2 or 3 is poor in a routine care setting using conventional DMARDs according to current practice.

     

     

     

     

     

     

     

     

     

     

     

     

     

    中等疾病活动度的RA患者持续传统治疗的结果:来自ERAN的数据

    Kiely P,et al.Rheumatology (Oxford). 2010 Dec 17.

     

    目的:报道早期RA网络(ERAN)中新近诊断的RA患者使用DMARD治疗,并根据第1DAS28分层,报告其第2年和第3DAS28HAQ结果。

     

    方法:ERAN是一个新近诊断RA患者的前瞻性观察性队列,由当地临床中心进行监测和治疗,在初次就诊、3-6个月、第1年填写标准化病例报告表,之后每年一次。

     

    结果:2002-2008年,在22ERAN中心共有418例新近诊断的RA患者完成2年随访,302例患者完成3年随访。第1年内,67%接受DMARDs单药治疗,26%联合DMARDs治疗,其中2%使用TNF抑制剂。在第1年至第3年,60%接受DMARDs单药治疗,34%联合DMARDs治疗,其中8%使用TNF抑制剂。74%1DAS28 <3.2患者和27% DAS28 3.2-5.1的患者在第2DAS28 <3.2OR 7.64; 95% CI 4.6, 12.6),71%35%分别在第3DAS28 <3.279%1DAS28 <3.2患者和52% DAS28 3.2-5.1的患者在第2HAQ <1.25OR 3.47; 95% CI 2.1, 5.6),81%47%分别在第3HAQ <1.25OR 4.92; 95% CI 2.6, 9.0)。

     

    结论:在目前的临床工作中、使用传统DMARDs情况下,第1DAS28 3.2-5.1RA患者在第2年或第3年达到DAS28 <3.2HAQ积分低的可能性较小。

  • 相关阅读:
    教你用笔记本破解无线路由器password
    EJB究竟是什么,真的那么神奇吗??
    Hibernate的介绍
    编程基本功训练:流程图画法及练习
    一年成为Emacs高手(像神一样使用编辑器)
    MfC 进度条控件
    最小生成树(普利姆算法、克鲁斯卡尔算法)
    创建与删除索引
    hdu 4876 ZCC loves cards(暴力)
    springMVC3学习(二)--ModelAndView对象
  • 原文地址:https://www.cnblogs.com/T2T4RD/p/5464333.html
Copyright © 2020-2023  润新知